<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240726062545N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-08-03</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of  extract of rosa canina fruit on orthostatic hypotension</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of  extract of rosa canina fruit on orthostatic hypotension in people with type 2 diabetes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-09-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/78234</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, one of the groups is denoted by the letter A and the other group by the letter B. Then, the random allocation list is prepared by using the simple randomization method and through the Random allocation software version 2.0 by the statistical consultant. In this way, it is determined which of the types of drug packages each patient will receive based on the order of entry into the study(A or B).
The drug and placebo are packed in similar containers by the drug supplier and labeled with the letters A and B. Which letter indicates which intervention is determined by the drug supplier during labeling, and Until the completion of the study, no one other than her/him will be informed about this issue, Blinding description: Patient: Capsules containing medicine and placebo are completely similar in terms of shape, color and packaging. Due to the fact that rosa canina  has a pleasant smell and the drug and placebo can be distinguished by the smell, so somerosa canina  essential oil will be added to the content of the placebo so that they are almost similar in smell.
Principal Investigator: The concerned resident will receive identical sealed medication packages marked with the letter A or B and will not be informed of which drug/placebo is contained in each medication package.
Statistical consultant: She prepares the randomization list for two letters A and B, but she will not know which letter represents the intervention and which represents the control.</study_design>
      <phase>3</phase>
      <hc_freetext>orthostatic hypotension.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In addition to health recommendations such as drinking large amounts of fluids and increasing salt intake and following a diet, a 500 mg capsule containing water extract powder of Rosa canina   with ID (voucher number I.SE.009), which is prepared as a capsule It is prepared from a pharmaceutical company affiliated with the Hellal Ahmar , it is used twice a day for 4 weeks. The standardization of the drug is based on total polyphenol as gallic acid. Intervention 2: Control group: In addition to health recommendations, such as drinking large amounts of fluids and increasing salt intake and following a diet, 500 mg placebo capsules containing starch powder and 1% Rosa canina essential oil are used every 12 hours for a month.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Morvarid Salamati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ebn Sina Blvd, Shahid Sadoughi Hospital</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8915887857</zip>
        <telephone>0003538224000</telephone>
        <email>m.salamati78@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Morvarid Salamati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ebn Sina Blvd, Shahid Sadoughi Hospital</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8915887857</zip>
        <telephone>000353822400</telephone>
        <email>m.salamati78@ gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age above 18 years
Suffering from type 2 diabetes
Suffering from orthostatic hypotension based on internal specialist's diagnosis</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Recent stroke or heart attack
Having heart rhythm disorders
uncontrolled blood pressure
end-stage renal disease (ESRD)
neuromuscular disease
heart failure (CHF)
HA1C level greater than 9
GFR less than 30
People who are treated with prazosin and tamsulosin</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I95.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Orthostatic hypotension</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In addition to health recommendations such as drinking large amounts of fluids and increasing salt intake and following a diet, a 500 mg capsule containing water extract powder of Rosa canina   with ID (voucher number I.SE.009), which is prepared as a capsule It is prepared from a pharmaceutical company affiliated with the Hellal Ahmar , it is used twice a day for 4 weeks. The standardization of the drug is based on total polyphenol as gallic acid.</i_keyword>
      <i_keyword>Control group: In addition to health recommendations, such as drinking large amounts of fluids and increasing salt intake and following a diet, 500 mg placebo capsules containing starch powder and 1% Rosa canina essential oil are used every 12 hours for a month.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Orthostatic hypotension. Timepoint: Measurement of orthostatic hypotension at the beginning of the study and one month after the consumption of the rosa canina extract. Method of measurement: Use of sphygmomanometer.</prim_outcome>
      <prim_outcome>Orthostatic Intolerance* Questionnaire (OIQ) score. Timepoint: Measurement of Orthostatic Intolerance* Questionnaire (OIQ) score at the beginning of the study and one month after consumption of Rosa canina extract. Method of measurement: Orthostatic Intolerance* Questionnaire (OIQ).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-07-06</approval_date>
        <contact_name>Research Ethics commitee of School of Medicine -Shahid Sadoughi University of Medical Sciences</contact_name>
        <contact_address>Ebne sina Blvd ,Shahid Sadoughi Hospital Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
